

Earnings of FY2017/3 1H

FUJIFILM Holdings Corporation

Oct. 27, 2016

FORWARD-LOOKING STATEMENTS

Forward-looking statements, such as those relating to earnings forecasts and other projections contained in this material, are management's current assumptions and beliefs based on currently available information. Such forward-looking statements are subject to a number of risks, uncertainties, and other factors. Accordingly, actual results may differ materially from those projected due to various factors.

Consolidated Performance for FY2017/3 1H

(Apr. 2016 – Sep. 2016)

(Billions of yen)

	FY2016/3 1H	FY2017/3 1H	Change	Influence of	
				exchange rate	Currency-neutral basis
Revenue	1,226.1 100.0%	1,120.9 100.0%	(105.2) -8.6%	(98.9)	(6.3) -0.5%
Operating Income	80.7 6.6%	63.5 5.7%	(17.2) -21.3%	(23.3)	6.1 +7.5%
Income before Income Taxes	84.6 6.9%	60.6 5.4%	(24.0) -28.4%		
Net Income Attributable to FUJIFILM Holdings	46.9 3.8%	33.5 3.0%	(13.4) -28.5%		
Net Income Attributable to FUJIFILM Holdings per Share	¥98.84	¥74.67	¥(24.17)		
Exchange Rates					
US\$/¥	¥122	¥105	¥(17)		
€/¥	¥135	¥118	¥(17)		

〈Other factors of change (YoY)〉

Operating income --- Raw material prices: + ¥5.5 billion

Consolidated Revenue and Operating Income by Segments

(Billions of yen)

Revenue	1H		Change				
	FY2016/3	FY2017/3			Influence of exchange rate	Currency-neutral basis	
Imaging Solutions	173.1	153.2	(19.9)	(-11.5%)	(20.6)	0.7	(+0.4%)
Information Solutions	460.4	431.6	(28.8)	(-6.3%)	(41.9)	13.1	(+2.8%)
Document Solutions	592.6	536.1	(56.5)	(-9.5%)	(36.4)	(20.1)	(-3.4%)
Total	1,226.1	1,120.9	(105.2)	(-8.6%)	(98.9)	(6.3)	(-0.5%)

Note: After elimination of intersegment transaction.

(Billions of yen)

Operating Income	1H		Change				
	FY2016/3	FY2017/3			Influence of exchange rate	Currency-neutral basis	
Imaging Solutions	12.4	8.9	(3.5)	(-28.5%)	(6.2)	2.7	(+21.7%)
Information Solutions	34.8	32.7	(2.1)	(-6.0%)	(10.7)	8.6	(+24.7%)
Document Solutions	48.3	36.9	(11.4)	(-23.7%)	(6.4)	(5.0)	(-10.5%)
Corporate Expenses & Eliminations	(14.8)	(15.0)	(0.2)		0.0	(0.2)	
Total	80.7	63.5	(17.2)	(-21.3%)	(23.3)	6.1	(+7.5%)

Summary by Operating Segment

(Billions of yen)

■ Imaging Solutions

Revenue	YoY		Operating income	YoY	
153.2	(19.9)	(-11.5%)	8.9	(3.5)	(-28.5%)

- In the photo imaging business, while the overall sales decreased due to the negative impact of yen appreciation and other factors, the sales of instant photo systems such as the *instax* series and *instax* films, remained strong especially in the United States and Europe. The high-value-added printing businesses such as the *photobook* services expanded.
- In the electronic imaging field, the sales of digital cameras decreased due to the negative impact of yen appreciation and other factors, while the sales of such flagship models of the mirrorless digital camera as *FUJIFILM X-Pro2* and *FUJIFILM X-T2*, and interchangeable lenses increased steadily.
- In the optical device field, the sales decreased due to the sales decrease of camera modules for use in smartphones.

Though revenue and operating income decreased due to the negative impact of yen appreciation and other factors, both of them on an operating basis increased.

Summary by Operating Segment

Information Solutions

(Billions of yen)					
Revenue	YoY		Operating income	YoY	
431.6	(28.8)	(-6.3%)	32.7	(2.1)	(-6.0%)

- In the medical systems business, the overall sales decreased due to the negative impact of yen appreciation and other factors, while steady sales persisted in the growth fields such as medical IT. In the pharmaceutical business, revenue decreased mainly due to the influence of generic drugs in the small-molecular pharmaceuticals, though the sales of contract manufacturing of biopharmaceuticals proceeded steadily. In the regenerative medicine business, Fujifilm has been promoting activities to expand its business field.
- In the FPD materials business, the overall sales increased due to the steady sales. Especially, the sales of *WV film* largely increased.
- In the industrial products business, the overall sales decreased due to the negative impact of yen appreciation and other factors, while the sales *EXCLEAR* were strong. In the electronic materials business, the overall sales increased, reflecting steady sales of such advanced products as peripheral materials related to photolithography.
- In the recording media business, the overall sales business remained almost unchanged mainly due to the negative impact of yen appreciation and other factors, while sales of computer tape, which has unique technologies, proceeded steadily.
- In the graphic systems business, the overall sales decreased due to the negative impact of yen appreciation and other factors, while steady sales were seen in digital printing devices.

Though revenue and operating income decreased due to the negative impact of yen appreciation and other factors, both of them on an operating basis increased.

Summary by Operating Segment

(Billions of yen)

Document Solutions

Revenue	YoY		Operating income	YoY	
536.1	(56.5)	(-9.5%)	36.9	(11.4)	(-23.7%)

- Regarding the office products business, the overall sales volume remained unchanged from the previous fiscal year. In Japan the sales of monochrome models were strong. In Asia-Oceania region, sales volume of both monochrome models and full-color models increased.
- In the office printers business, overall sales volume decreased due to the decrease particularly in export shipments to the United States and Europe. However, strong sales of monochrome models were seen in Asia-Oceania region.
- Regarding the production services business, the overall sales volume decreased, while sales volume increased in Japan.
- In the global services business, managed print service business proceeded smoothly both in Japan and Asia-Oceania region.

Revenue and operating income decreased reflecting the negative impact of depreciation of Asian currencies, sales decrease in export shipments to the United States and Europe, and other factors.

Consolidated Balance Sheet

(Billions of yen)

	Mar.15	Mar.16	Sep.16	Change from Mar.16
Cash and cash equivalents	726.9	600.9	650.0	49.1
Notes and accounts receivable	681.0	663.9	566.1	(97.8)
Inventories	372.5	352.9	341.2	(11.7)
Other current assets	162.8	171.6	138.4	(33.2)
Total current assets	1,943.2	1,789.3	1,695.7	(93.6)
Property, plant and equipment	527.4	534.1	514.9	(19.2)
Goodwill, net	505.0	506.9	477.3	(29.6)
Investment securities and other	581.0	533.4	486.8	(46.6)
Total noncurrent assets	1,613.4	1,574.4	1,479.0	(95.4)
Total assets	3,556.6	3,363.7	3,174.7	(189.0)

	Mar.15	Mar.16	Sep.16	Change from Mar.16
Short-term and long-term debt	349.7	365.7	381.9	16.2
Notes and accounts payable	269.0	259.3	228.2	(31.1)
Other liabilities	470.5	454.8	407.9	(46.9)
Total liabilities	1,089.2	1,079.8	1,018.0	(61.8)
Total FUJIFILM Holdings shareholders' equity	2,232.7	2,054.5	1,935.6	(118.9)
Noncontrolling interests	234.7	229.4	221.1	(8.3)
Total equity	2,467.4	2,283.9	2,156.7	(127.2)
Total liabilities and equity	3,556.6	3,363.7	3,174.7	(189.0)


(yen)

Exchange Rates	Mar.15	Mar.16	Sep.16	Change from Mar.16
US\$/¥	¥120	¥113	¥101	¥(12)
€/¥	¥130	¥128	¥113	¥(15)

Cash Flows

- C/F from operating activities
- C/F from investing activities
- Free cash flows (without acquisitions of businesses)

(Billions of yen)



(Billions of yen)

	FY2015/3 1H	FY2016/3 1H	FY2017/3 1H
Net income	48.8	55.7	40.3
Depreciation & amortization	59.1	57.5	56.9
Change in notes and accounts receivable	40.0	43.5	55.9
Change in inventories	(3.8)	(5.5)	(10.1)
Change in notes and accounts payable-trade	(19.7)	(20.3)	(9.1)
Others	4.8	(34.7)	4.1
C/F from operating activities	129.2	96.2	138.0
Capital expenditure	(32.2)	(29.1)	(39.3)
Purchases of software	(10.6)	(12.1)	(10.6)
Sales and purchases of marketable and investment securities	(20.2)	3.3	29.1
Acquisitions of businesses	0.0	(35.2)	(1.3)
Others	(16.0)	(18.6)	(11.5)
C/F from investing activities	(79.0)	(91.7)	(33.6)
Free cash flows	50.2	4.5	104.4

Free cash flows without acquisitions of businesses	50.2	39.7	105.7
--	------	------	-------

Consolidated Financial Forecast for FY2017/3

(as of Oct. 27, 2016)

(Billions of yen)

	FY2016/3	FY2017/3 (Previous forecast)	FY2017/3 (Latest revised forecast)	Change from previous forecast	Change from previous year
Revenue	2,491.6 100.0%	2,550.0 100.0%	2,400.0 100.0%	(150.0) -5.9%	(91.6) -3.7%
Operating Income	191.2 7.7%	220.0 8.6%	192.0 8.0%	(28.0) -12.7%	0.8 +0.4%
Income before Income Taxes	194.5 7.8%	220.0 8.6%	192.0 8.0%	(28.0) -12.7%	(2.5) -1.3%
Net Income Attributable to FUJIFILM Holdings	123.3 4.9%	125.0 4.9%	112.0 4.7%	(13.0) -10.4%	(11.3) -9.2%
Net Income Attributable to FUJIFILM Holdings per Share	¥264.87	¥277.47	¥252.51	¥(24.96)	¥(12.36)
ROE	5.8%	6 to 7%	around 6%	—	—
Exchange Rates US\$/¥	¥120	¥110	¥105	¥(5)	¥(15)
€/¥	¥133	¥125	¥117	¥(8)	¥(16)
Silver Price (/kg)	¥60,000	¥60,000	¥60,000	—	—

Note: Impact of exchange rate movements on operating income (FY2017/3 full year) US\$/¥: ¥0.8 billion €/¥: ¥0.8 billion
 Estimated currency exchange rate of 2H US\$/¥: ¥105 €/¥: ¥115

FUJIFILM

Value from Innovation

At Fujifilm, we are continuously innovating — creating new technologies, products and services that inspire and excite people everywhere.

Our goal is to empower the potential and expand the horizons of tomorrow's businesses and lifestyles.

FUJIFILM Holdings Corporation

Corporate Communication Office, Corporate Planning Div.

<http://www.fujifilmholdings.com/en/index.html>



Earnings for FY2017/3 1H

Appendix

Earnings for FY2017/3 2Q/1H

(Billions of yen)

	FY2016/3 2Q	FY2017/3 2Q	Change	FY2016/3 1H	FY2017/3 1H	Change
Revenue	635.2 100.0%	573.9 100.0%	(61.3) -9.6%	1,226.1 100.0%	1,120.9 100.0%	(105.2) -8.6%
Operating Income	44.5 7.0%	35.9 6.3%	(8.6) -19.3%	80.7 6.6%	63.5 5.7%	(17.2) -21.3%
Income before Income Taxes	40.0 6.3%	38.9 6.8%	(1.1) -2.8%	84.6 6.9%	60.6 5.4%	(24.0) -28.4%
Net Income Attributable to FUJIFILM Holdings	22.6 3.6%	22.3 3.9%	(0.3) -1.1%	46.9 3.8%	33.5 3.0%	(13.4) -28.5%
Exchange Rates						
US\$/¥	¥122	¥102	¥(20)	¥122	¥105	¥(17)
€/¥	¥136	¥114	¥(22)	¥135	¥118	¥(17)

〈Factors of change (1H YoY)〉 Operating income ---Exchange rate fluctuations: ¥ (23.3) billion,
Raw material prices: + ¥ 5.5 billion

Earnings for FY2017/3 2Q/1H

(Billions of yen)

Revenue	2Q				1H			
	FY2016/3	FY2017/3	Change		FY2016/3	FY2017/3	Change	
Imaging Solutions	88.2	76.5	(11.7)	(-13.2%)	173.1	153.2	(19.9)	(-11.5%)
Information Solutions	242.3	223.8	(18.5)	(-7.6%)	460.4	431.6	(28.8)	(-6.3%)
Document Solutions	304.7	273.6	(31.1)	(-10.2%)	592.6	536.1	(56.5)	(-9.5%)
Total	635.2	573.9	(61.3)	(-9.6%)	1,226.1	1,120.9	(105.2)	(-8.6%)

Note: After elimination of intersegment transaction.

(Billions of yen)

Operating Income [Operating Margin]	2Q				1H			
	FY2016/3	FY2017/3	Change		FY2016/3	FY2017/3	Change	
Imaging Solutions	7.9 [8.9%]	3.6 [4.7%]	(4.3)	(-54.5%)	12.4 [7.1%]	8.9 [5.7%]	(3.5)	(-28.5%)
Information Solutions	19.9 [8.2%]	17.7 [7.9%]	(2.2)	(-11.0%)	34.8 [7.5%]	32.7 [7.6%]	(2.1)	(-6.0%)
Document Solutions	24.2 [7.9%]	22.3 [8.1%]	(1.9)	(-8.3%)	48.3 [8.1%]	36.9 [6.8%]	(11.4)	(-23.7%)
Corporate Expenses & Eliminations	(7.5)	(7.7)	(0.2)		(14.8)	(15.0)	(0.2)	
Total	44.5 [7.0%]	35.9 [6.3%]	(8.6)	(-19.3%)	80.7 [6.6%]	63.5 [5.7%]	(17.2)	(-21.3%)

FY2017/3 2Q (3 Months) Performance by Operating Segment

■ Imaging Solutions

- In the photo imaging business, while the overall sales decreased due to the negative impact of yen appreciation and other factors, the sales of instant photo systems increased especially in the United States and Europe.
- In the electronic imaging field, while the overall sales decreased due to the negative impact of yen appreciation and other factors, the sales of flagship models of the mirrorless digital camera *FUJIFILM X-T2*, which was launched in September sold well.

■ Information Solutions

- In the medical systems business, the overall sales decreased due to the negative impact of yen appreciation and other factors, while sales proceeded steadily in the growth fields such as medical IT, IVD(in-vitro diagnostics). In the pharmaceutical business revenue decreased mainly due to the influence of generic drugs in the small-molecular pharmaceuticals.
- In the FPD materials business, the sales of *WV film* increased largely.
- In the industrial products business, the overall sales decreased due to the negative impact of yen appreciation, while the sales of touch-panel sensor films *EXCLEAR* were steady. In the electronic materials business, the sales of advanced products of peripheral materials related to photolithography proceeded steadily.

■ Document Solutions

- Both revenue and profit decreased due to the negative impact of depreciation of Asian currencies and other factors.

Earnings for FY2017/3 2Q/1H

■ Imaging Solutions

(Billions of yen)

Revenue	2Q				1H			
	FY2016/3	FY2017/3	Change		FY2016/3	FY2017/3	Change	
Photo Imaging	61.8	53.0	(8.8)	(-14.0%)	120.1	105.6	(14.5)	(-12.0%)
Electronic Imaging	16.2	15.1	(1.1)	(-6.6%)	32.5	31.0	(1.5)	(-4.5%)
Optical Devices	10.2	8.4	(1.8)	(-18.6%)	20.5	16.6	(3.9)	(-19.2%)
Optical Device & Electronic Imaging Products	26.4	23.5	(2.9)	(-11.3%)	53.0	47.6	(5.4)	(-10.2%)
Total	88.2	76.5	(11.7)	(-13.2%)	173.1	153.2	(19.9)	(-11.5%)

Note: After elimination of intersegment transaction.


(Billions of yen)

Operating Income [Operating Margin]	2Q				1H			
	FY2016/3	FY2017/3	Change		FY2016/3	FY2017/3	Change	
Imaging Solutions	7.9 [8.9%]	3.6 [4.7%]	(4.3)	(-54.5%)	12.4 [7.1%]	8.9 [5.7%]	(3.5)	(-28.5%)

Change in Quarterly Earnings by Operating Segment

■ Imaging Solutions

(Billions of yen)



Earnings for FY2017/3 2Q/1H

Information Solutions

(Billions of yen)

Revenue	2Q				1H																					
	FY2016/3	FY2017/3	Change		FY2016/3	FY2017/3	Change																			
Healthcare	104.0	97.0	(7.0)	(-6.7%)	192.0	180.1	(11.9)	(-6.2%)																		
FPD Materials	24.7	24.8	0.1	(+0.4%)	45.6	48.5	2.9	(+6.4%)																		
Industrial Products	26.9	26.5	(0.4)	(-1.6%)	52.2	51.7	(0.5)	(-0.9%)																		
Electronic Materials	51.6	51.3	(0.3)	(-0.6%)	97.8	100.2	2.4	(+2.5%)																		
Highly Functional Materials	11.0	11.9	0.9	(+7.5%)	21.8	21.7	(0.1)	(-0.8%)																		
Recording Media	74.0	63.1	(10.9)	(-14.6%)	145.5	127.2	(18.3)	(-12.5%)																		
Graphic Systems	1.7	0.5	(1.2)	(-69.9%)	3.3	2.4	(0.9)	(-29.2%)	Others	242.3	223.8	(18.5)	(-7.6%)	460.4	431.6	(28.8)	(-6.3%)	Total								
Others	242.3	223.8	(18.5)	(-7.6%)	460.4	431.6	(28.8)	(-6.3%)																		
Total																										

Note: After elimination of intersegment transaction.

(Billions of yen)

Operating Income [Operating Margin]	2Q				1H			
	FY2016/3	FY2017/3	Change		FY2016/3	FY2017/3	Change	
Information Solutions	19.9 [8.2%]	17.7 [7.9%]	(2.2)	(-11.0%)	34.8 [7.5%]	32.7 [7.6%]	(2.1)	(-6.0%)


Change in Quarterly Earnings by Operating Segment

Information Solutions

(Billions of yen)

Revenue

Operating Income



Earnings for FY2017/3 2Q/1H

Document Solutions

(Billions of yen)

Revenue	2Q				1H			
	FY2016/3	FY2017/3	Change		FY2016/3	FY2017/3	Change	
Office Products	131.2	118.8	(12.4)	(-9.5%)	256.7	237.6	(19.1)	(-7.4%)
Office Printers	48.6	41.8	(6.8)	(-14.0%)	100.1	81.0	(19.1)	(-19.1%)
Production Services	42.5	35.7	(6.8)	(-15.9%)	80.5	69.3	(11.2)	(-13.9%)
Global Services	50.3	48.2	(2.1)	(-4.3%)	94.3	92.8	(1.5)	(-1.7%)
Others	32.1	29.1	(3.0)	(-9.1%)	61.0	55.4	(5.6)	(-9.1%)
Total	304.7	273.6	(31.1)	(-10.2%)	592.6	536.1	(56.5)	(-9.5%)

Note: After elimination of intersegment transaction.

(Billions of yen)

Operating Income [Operating Margin]	2Q				1H			
	FY2016/3	FY2017/3	Change		FY2016/3	FY2017/3	Change	
Document Solutions	24.2 [7.9%]	22.3 [8.1%]	(1.9)	(-8.3%)	48.3 [8.1%]	36.9 [6.8%]	(11.4)	(-23.7%)


Change in Quarterly Earnings by Operating Segment

Document Solutions

(Billions of yen)

Revenue

Operating Income



Revenue from Domestic and Overseas


(Billions of yen)

	FY2016/3 1H		FY2017/3 1H		Change	
	Ratio (%)		Ratio (%)			
Domestic	39.0%	478.0	42.0%	470.2	(7.8)	(-1.6%)
The Americas	21.1%	258.3	19.3%	217.0	(41.3)	(-16.0%)
Europe	11.1%	136.4	11.1%	124.5	(11.9)	(-8.7%)
China	11.3%	138.9	11.5%	129.3	(9.6)	(-6.9%)
Asia and others	28.8%	353.4	27.6%	309.2	(44.2)	(-12.5%)
Overseas	61.0%	748.1	58.0%	650.7	(97.4)	(-13.0%)
Consolidated total	100.0%	1,226.1	100.0%	1,120.9	(105.2)	(-8.6%)


Capital Expenditure , Depreciation & Amortization

- Corporate □ Document
- Information □ Imaging

Capital Expenditure
(1H)



Depreciation & Amortization
(1H)



(Billions of yen)

	2Q			1H			Full year		
	FY 2015/3	FY 2016/3	FY 2017/3	FY 2015/3	FY 2016/3	FY 2017/3	FY 2015/3	FY 2016/3	FY2017/3 (forecast)
Imaging	2.9	3.1	3.1	4.4	4.9	5.2	7.9	10.1	-
Information	8.0	5.9	8.0	14.6	13.0	17.6	29.3	39.3	-
Document	5.5	6.3	6.0	9.4	10.0	10.3	17.3	23.3	-
Corporate	0.4	0.4	0.4	0.7	0.6	0.5	1.6	1.4	-
Capex *	16.8	15.7	17.5	29.1	28.5	33.6	56.1	74.1	89.0
Imaging	2.4	2.6	2.8	4.8	5.7	5.8	11.1	12.9	-
Information	12.7	12.9	12.2	24.9	25.6	24.7	51.0	52.0	-
Document	14.4	12.8	11.9	28.3	25.2	25.4	58.7	54.5	-
Corporate	0.5	0.6	0.5	1.1	1.0	1.0	2.1	2.0	-
Depreciation & Amortization	30.0	28.9	27.4	59.1	57.5	56.9	122.9	121.4	113.0
Depreciation*	16.6	15.5	14.7	32.3	30.7	28.8	65.1	65.9	62.0

*Note: Figures do not include amounts for rental equipment handled by the Document Solutions segment and others.

R&D Expenses, SG&A Expenses

- Imaging
- Information
- Document
- Corporate

R&D Expenses (1H)



(Billions of yen)

	2Q		1H		Full year	
	FY2016/3	FY2017/3	FY2016/3	FY2017/3	FY2016/3	FY2017/3 (forecast)
Imaging	2.2	2.1	3.9	4.3	8.0	-
Information	17.3	16.8	34.8	32.0	67.3	-
Document	16.2	16.2	32.2	32.6	63.2	-
Corporate	6.1	6.1	12.0	12.1	24.5	-
R&D Expenses	41.8	41.2	82.9	81.0	163.0	160.0
<ratio to revenue>	6.6%	7.2%	6.8%	7.2%	6.5%	6.7%
SG&A Expenses	162.5	149.0	317.0	300.3	622.4	-
<ratio to revenue>	25.6%	25.9%	25.8%	26.8%	25.0%	-

Exchange Rates, Raw Material Prices, and Number of Employees

Exchange Rates

(yen)

	FY2016/3						FY2017/3			
	1Q	2Q	1H	3Q	4Q	Full year	1Q	2Q	1H	Full year (forecast)
US\$/¥	121	122	122	122	115	120	108	102	105	105
€/¥	134	136	135	133	128	133	122	114	118	117

Raw Material Prices (Average)

(¥1,000/kg)

	FY2016/3						FY2017/3			
	1Q	2Q	1H	3Q	4Q	Full year	1Q	2Q	1H	Full year (forecast)
Silver	64	60	62	58	54	60	57	63	59	60

Number of Employees

	2015.Sep	2015.Dec	2016.Mar	2016.Jun	2016.Sep
Consolidated Total	78,158	77,928	78,150	78,882	78,976

Consolidated Financial Forecast for FY2017/3 by Segments (as of Oct. 27, 2016)

(Billions of yen)

Revenue	FY2016/3	FY2017/3 (Previous forecast)	FY2017/3 (Latest revised forecast)	Change from previous forecast	Change from previous year
Imaging Solutions	353.3	365.0	335.0	(30.0)	(18.3)
Information Solutions	964.2	985.0	935.0	(50.0)	(29.2)
Document Solutions	1,174.1	1,200.0	1,130.0	(70.0)	(44.1)
Total	2,491.6	2,550.0	2,400.0	(150.0)	(91.6)


Note: After elimination of intersegment transaction.

Operating Income	FY2016/3	FY2017/3 (Previous forecast)	FY2017/3 (Latest revised forecast)	Change from previous forecast	Change from previous year
Imaging Solutions	32.2	38.0	32.0	(6.0)	(0.2)
Information Solutions	94.1	102.0	94.0	(8.0)	(0.1)
Document Solutions	94.9	110.0	96.0	(14.0)	1.1
Corporate Expenses & Eliminations	(30.0)	(30.0)	(30.0)	0.0	0.0
Total	191.2	220.0	192.0	(28.0)	0.8

Shareholder Returns

■ Dividend

Dividend for FY2017/3 is planned ¥70 per share, increased ¥5 from previous fiscal year. The dividend increase will be the 7 consecutive years.



Pipeline

Development code	Therapeutic category	Formulation	Region	Development stage	Note
T-705	Anti-influenza drug	Oral	Japan	Approved	Approved in March 2014 (AVIGAN®)
			U.S.A.	P III	Under clinical trials utilizing subsidy from the U.S. Department of Defense
T-3811	Quinolone synthetic antibacterial drug	Oral	China	Submitted an application for permission	Already launched as <i>Geninax</i> in Japan
T-2307	Antifungal drug	Injection	U.S.A.	P I completed	
T-817MA	Alzheimer's disease drug	Oral	U.S.A.	P II	Undertaking clinical trials with the Alzheimer's Disease Cooperative Study
			Japan	P II	Engaging in the search and identification of biomarkers with the CiRA of Kyoto University
T-4288	Macrolide antibacterial drug	Oral	Japan	P II	
ITK-1	Bio Castration-resistant prostate cancer drug	Injection	Japan	P III	
FF-10501	Relapsed or Refractory myelodysplastic syndrome drug	Oral	Japan	P I completed	
			U.S.A.	P I	Promoting clinical trial with the MD Anderson Cancer Center
FF-10502	Advanced/recurrent pancreatic/ovarian cancer drug	Injection	U.S.A.	P I	Promoting clinical trial with the MD Anderson Cancer Center
			Europe /Japan	Under non-clinical trial	
FF-21101	Bio Advanced/recurrent non-small cell lung/pancreatic cancer drug (armed antibody)	Injection	U.S.A.	P I	Promoting clinical trial with the MD Anderson Cancer Center
			Europe /Japan	Under non-clinical trial	
F-1311	Diagnostic drug for prostate cancer (Radiopharmaceuticals)		Japan	P II	
FF-10101	Acute Myeloid Leukemia (AML) drug	Oral	U.S.A.	Under non-clinical trial	

Note: FKB327 (a biosimilar of adalimumab) of FUJIFILM KYOWA KIRIN Biologics (FKB), an equity method affiliated company is under phase III clinical trial in U.S.A. and other countries. FKB238 (a biosimilar of bevacizumab) of JV between FKB and AstraZeneca is under phase III clinical trial in U.S.A., Europe, and others.

Appendix

[FUJIFILM Holdings – Investor Relations](#)

<http://www.fujifilmholdings.com/en/investors/index.html>

[FUJIFILM Holdings Annual Report 2016](#)

http://www.fujifilmholdings.com/en/investors/annual_reports/2016/index.html

[IR Events Materials](#)

http://www.fujifilmholdings.com/en/investors/ir_events/business_presentations/index.html

- Business presentation materials
- Dec. 2015 Business Presentation for Electronic Materials Business
- Mar. 2016 Presentation of R&D activities
- May 2016 Presentation of Document Solutions

[What Kind of Company is Fujifilm?](#)

<http://www.fujifilmholdings.com/en/investors/guidance/index.html>

FUJIFILM

Value from Innovation

At Fujifilm, we are continuously innovating — creating new technologies, products and services that inspire and excite people everywhere.

Our goal is to empower the potential and expand the horizons of tomorrow's businesses and lifestyles.

FUJIFILM Holdings Corporation

Corporate Communication Office, Corporate Planning Div.

<http://www.fujifilmholdings.com/en/index.html>